These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21872471)

  • 41. Facioscapulohumeral muscular dystrophy.
    Padberg GW; van Engelen BG
    Curr Opin Neurol; 2009 Oct; 22(5):539-42. PubMed ID: 19724227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AChR-seropositive myasthenia gravis in muscular dystrophy: diagnostic pitfalls and clinical management challenges.
    Avallone AR; Di Stefano V; Bevilacqua L; Alonge P; Lupica A; Maccora S; Monastero R; Amabile S; Barone P; Brighina F; Vinciguerra C
    Neurol Sci; 2024 Jul; ():. PubMed ID: 38965114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Facioscapulohumeral muscular dystrophy - twelve cases from two pedigrees].
    An R; Xu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):402-3. PubMed ID: 24928028
    [No Abstract]   [Full Text] [Related]  

  • 44. Best practice guidelines on genetic diagnostics of Facioscapulohumeral muscular dystrophy: workshop 9th June 2010, LUMC, Leiden, The Netherlands.
    Lemmers RJ; O'Shea S; Padberg GW; Lunt PW; van der Maarel SM
    Neuromuscul Disord; 2012 May; 22(5):463-70. PubMed ID: 22177830
    [No Abstract]   [Full Text] [Related]  

  • 45. Bringing smiles to faces: Evidence-based guidelines for facioscapulohumeral dystrophy.
    Iyadurai S; Kissel JT
    Muscle Nerve; 2015 Aug; 52(2):161-2. PubMed ID: 26111624
    [No Abstract]   [Full Text] [Related]  

  • 46. [Facioscapulohumeral muscular dystrophy].
    Pospisilova J; Bjørnarå B; Bjørnarå KA
    Tidsskr Nor Laegeforen; 2021 Mar; 141(4):. PubMed ID: 33685096
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of acetylcholine receptor source on detection and quantification of anti-acetylcholine receptor-binding antibody.
    Haven TR; Lyons BW; Pasi BM; Wu LL; Astill ME; Hill HR
    Clin Chem; 2008 Sep; 54(9):1580-1. PubMed ID: 18755912
    [No Abstract]   [Full Text] [Related]  

  • 48. The identification of Landouzy-Dejerine disease: an investigative history.
    Jacqueline M
    Neuromuscul Disord; 2011 Apr; 21(4):291-7. PubMed ID: 21316966
    [No Abstract]   [Full Text] [Related]  

  • 49. Immune-mediated necrotizing myopathies are serologically heterogeneous and autoantibodies may predict their clinical phenotype: two cases associated with anti-Pl7 antibodies.
    Meyer A; Messer L; Goetz J; Lannes B; Weber JC; Geny B; Gottenberg JE; Sibilia J
    Scand J Rheumatol; 2014; 43(1):81-3. PubMed ID: 24446708
    [No Abstract]   [Full Text] [Related]  

  • 50. The development of myasthenia gravis in a patient with facioscapulohumeral muscular dystrophy: case report and literature review.
    Nauman F; Hussain MFA; Burakgazi AZ
    Neurol Int; 2019 Sep; 11(3):8191. PubMed ID: 31579125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A rare case of facioscapulohumeral muscular dystrophy and myasthenia gravis.
    Asadollahi M; Rezaiyan B; Amjadi H
    Iran J Neurol; 2012; 11(1):28-9. PubMed ID: 24250856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Case Report of Congenital Fiber Type Disproportion with an Increased Level of Anti-ACh Receptor Antibodies.
    Kimura S; Ozasa S; Nomura K; Kosuge H; Yoshioka K
    Case Rep Pediatr; 2013; 2013():607678. PubMed ID: 23762716
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis.
    Oskarsson B; Ringel SP
    Neuromuscul Disord; 2013 Apr; 23(4):316-8. PubMed ID: 23453859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance.
    Lane RJ; Roncaroli F; Charles P; McGonagle DG; Orrell RW
    Neuromuscul Disord; 2012 Feb; 22(2):122-8. PubMed ID: 21872471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case of facioscapulohumeral muscular dystrophy and myasthenia gravis with positivity of anti-Ach receptor antibody: a fortuitous association?
    Filippelli E; Barone S; Granata A; Nisticò R; Valentino P
    Neurol Sci; 2019 Jan; 40(1):195-197. PubMed ID: 30215155
    [No Abstract]   [Full Text] [Related]  

  • 56. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients.
    Oshima M; Deitiker PR; Smith RG; Mosier D; Atassi MZ
    Autoimmunity; 2012 Mar; 45(2):153-60. PubMed ID: 21985279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.